Inhibikase Total Assets vs Short Long Term Debt Analysis

IKT Stock

USD 2.92 0.19 6.96%

Inhibikase Therapeutics financial indicator trend analysis is infinitely more than just investigating Inhibikase Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inhibikase Therapeutics is a good investment. Please check the relationship between Inhibikase Therapeutics Total Assets and its Short Long Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

Total Assets vs Short Long Term Debt

Total Assets vs Short Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inhibikase Therapeutics Total Assets account and Short Long Term Debt. At this time, the significance of the direction appears to have no relationship.

The correlation between Inhibikase Therapeutics' Total Assets and Short Long Term Debt is 0.0. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of Inhibikase Therapeutics, assuming nothing else is changed. The correlation between historical values of Inhibikase Therapeutics' Total Assets and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Inhibikase Therapeutics are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Total Assets i.e., Inhibikase Therapeutics' Total Assets and Short Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.0

Relationship Direction	Flat
Relationship Strength	Insignificant

View All Relationships

Total Assets

Total assets refers to the total amount of Inhibikase Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Inhibikase Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Most indicators from Inhibikase Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inhibikase Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.At this time, Inhibikase Therapeutics' Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.09 in 2024, despite the fact that Enterprise Value is likely to grow to (1.9 M).

	2021	2022	2023	2024 (projected)
Cost Of Revenue	11.4M	6.7K	13.6M	14.3M
Depreciation And Amortization	14.8M	6.7K	177.4K	168.5K

Cost Of Revenue Depreciation And Amortization

Inhibikase Therapeutics fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Total Current Assets	Common Stock	Other Current Liab	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Net Invested Capital
Total Current Liabilities		0.58	-0.58	0.93	0.48	0.01	0.64	0.33	0.82	0.59	0.53	0.57	0.83	-0.56	0.58	-0.9	0.68	0.63	-0.73	0.52	-0.47	0.37	0.6	0.61	-0.88	0.57
Net Tangible Assets	0.58		-0.95	0.46	0.11	-0.21	0.8	0.43	0.76	0.82	0.68	0.82	0.81	-0.64	0.68	-0.68	0.86	0.83	-0.92	0.91	-0.36	0.6	0.96	-0.09	-0.77	0.82
Retained Earnings	-0.58	-0.95		-0.41	0.07	0.25	-0.61	-0.21	-0.73	-0.63	-0.84	-0.63	-0.78	0.42	-0.47	0.67	-0.78	-0.64	0.85	-0.94	0.58	-0.41	-0.9	0.12	0.78	-0.62
Accounts Payable	0.93	0.46	-0.41		0.49	-0.06	0.61	0.38	0.63	0.57	0.31	0.55	0.75	-0.54	0.55	-0.8	0.66	0.61	-0.72	0.34	-0.43	0.33	0.48	0.73	-0.78	0.55
Other Assets	0.48	0.11	0.07	0.49		0.63	0.49	0.37	0.47	0.46	-0.22	0.46	0.21	-0.62	0.59	-0.22	0.26	0.46	-0.23	-0.05	0.45	0.57	0.16	0.3	-0.14	0.47
Net Receivables	0.01	-0.21	0.25	-0.06	0.63		-0.13	-0.05	0.19	-0.14	-0.32	-0.12	-0.35	0.09	-0.11	0.38	-0.26	-0.16	0.29	-0.24	0.37	-0.03	-0.22	-0.26	0.39	-0.12
Total Current Assets	0.64	0.8	-0.61	0.61	0.49	-0.13		0.79	0.73	0.99	0.3	0.99	0.81	-0.93	0.93	-0.71	0.85	1.0	-0.85	0.66	0.04	0.76	0.86	0.27	-0.73	0.99
Common Stock	0.33	0.43	-0.21	0.38	0.37	-0.05	0.79		0.48	0.78	-0.11	0.78	0.48	-0.66	0.63	-0.35	0.52	0.76	-0.47	0.36	0.26	0.33	0.56	0.25	-0.39	0.78
Other Current Liab	0.82	0.76	-0.73	0.63	0.47	0.19	0.73	0.48		0.7	0.58	0.7	0.76	-0.59	0.61	-0.73	0.66	0.72	-0.7	0.74	-0.28	0.42	0.79	0.16	-0.77	0.7
Total Assets	0.59	0.82	-0.63	0.57	0.46	-0.14	0.99	0.78	0.7		0.28	1.0	0.77	-0.93	0.94	-0.68	0.83	1.0	-0.85	0.65	0.06	0.77	0.85	0.2	-0.7	1.0
Short Long Term Debt Total	0.53	0.68	-0.84	0.31	-0.22	-0.32	0.3	-0.11	0.58	0.28		0.27	0.73	-0.15	0.18	-0.65	0.64	0.31	-0.63	0.85	-0.73	0.22	0.7	0.06	-0.71	0.27
Total Stockholder Equity	0.57	0.82	-0.63	0.55	0.46	-0.12	0.99	0.78	0.7	1.0	0.27		0.76	-0.93	0.93	-0.65	0.82	1.0	-0.84	0.65	0.08	0.77	0.85	0.17	-0.68	1.0
Current Deferred Revenue	0.83	0.81	-0.78	0.75	0.21	-0.35	0.81	0.48	0.76	0.77	0.73	0.76		-0.67	0.68	-0.92	0.93	0.8	-0.92	0.82	-0.48	0.54	0.89	0.48	-0.95	0.75
Net Debt	-0.56	-0.64	0.42	-0.54	-0.62	0.09	-0.93	-0.66	-0.59	-0.93	-0.15	-0.93	-0.67		-1.0	0.66	-0.71	-0.93	0.71	-0.45	-0.27	-0.89	-0.68	-0.31	0.61	-0.93
Cash	0.58	0.68	-0.47	0.55	0.59	-0.11	0.93	0.63	0.61	0.94	0.18	0.93	0.68	-1.0		-0.68	0.72	0.94	-0.74	0.47	0.22	0.9	0.7	0.28	-0.64	0.93
Non Current Assets Total	-0.9	-0.68	0.67	-0.8	-0.22	0.38	-0.71	-0.35	-0.73	-0.68	-0.65	-0.65	-0.92	0.66	-0.68		-0.75	-0.72	0.81	-0.63	0.48	-0.48	-0.71	-0.6	0.98	-0.66
Non Currrent Assets Other	0.68	0.86	-0.78	0.66	0.26	-0.26	0.85	0.52	0.66	0.83	0.64	0.82	0.93	-0.71	0.72	-0.75		0.84	-0.96	0.83	-0.35	0.66	0.92	0.31	-0.8	0.82
Cash And Short Term Investments	0.63	0.83	-0.64	0.61	0.46	-0.16	1.0	0.76	0.72	1.0	0.31	1.0	0.8	-0.93	0.94	-0.72	0.84		-0.86	0.66	0.02	0.76	0.86	0.24	-0.74	1.0
Common Stock Total Equity	-0.73	-0.92	0.85	-0.72	-0.23	0.29	-0.85	-0.47	-0.7	-0.85	-0.63	-0.84	-0.92	0.71	-0.74	0.81	-0.96	-0.86		-0.81	0.43	-0.64	-0.91	-0.27	0.87	-0.83
Common Stock Shares Outstanding	0.52	0.91	-0.94	0.34	-0.05	-0.24	0.66	0.36	0.74	0.65	0.85	0.65	0.82	-0.45	0.47	-0.63	0.83	0.66	-0.81		-0.48	0.42	0.95	-0.07	-0.74	0.65
Non Current Liabilities Total	-0.47	-0.36	0.58	-0.43	0.45	0.37	0.04	0.26	-0.28	0.06	-0.73	0.08	-0.48	-0.27	0.22	0.48	-0.35	0.02	0.43	-0.48		0.3	-0.31	-0.22	0.57	0.09
Other Current Assets	0.37	0.6	-0.41	0.33	0.57	-0.03	0.76	0.33	0.42	0.77	0.22	0.77	0.54	-0.89	0.9	-0.48	0.66	0.76	-0.64	0.42	0.3		0.61	0.09	-0.42	0.77
Other Stockholder Equity	0.6	0.96	-0.9	0.48	0.16	-0.22	0.86	0.56	0.79	0.85	0.7	0.85	0.89	-0.68	0.7	-0.71	0.92	0.86	-0.91	0.95	-0.31	0.61		0.05	-0.8	0.85
Total Liab	0.61	-0.09	0.12	0.73	0.3	-0.26	0.27	0.25	0.16	0.2	0.06	0.17	0.48	-0.31	0.28	-0.6	0.31	0.24	-0.27	-0.07	-0.22	0.09	0.05		-0.49	0.17
Deferred Long Term Liab	-0.88	-0.77	0.78	-0.78	-0.14	0.39	-0.73	-0.39	-0.77	-0.7	-0.71	-0.68	-0.95	0.61	-0.64	0.98	-0.8	-0.74	0.87	-0.74	0.57	-0.42	-0.8	-0.49		-0.68
Net Invested Capital	0.57	0.82	-0.62	0.55	0.47	-0.12	0.99	0.78	0.7	1.0	0.27	1.0	0.75	-0.93	0.93	-0.66	0.82	1.0	-0.83	0.65	0.09	0.77	0.85	0.17	-0.68

Click cells to compare fundamentals

Inhibikase Therapeutics Account Relationship Matchups

Inhibikase Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	4.3M	4.7M	4.1M	3.7M	3.4M	3.7M
Net Tangible Assets	(778.0K)	(4.5M)	9.8M	38.4M	44.2M	46.4M
Retained Earnings	(12.2M)	(15.0M)	(29.8M)	(47.9M)	(66.9M)	(63.6M)
Accounts Payable	1.0M	1.7M	1.1M	1.2M	646.8K	1.0M
Other Assets	2.9K	829.2K	1.6M	1.0	1.15	1.09
Total Current Assets	35.4K	14.8M	42.5M	24.4M	14.2M	13.4M
Other Current Liab	1.7M	632.9K	2.7M	2.4M	2.3M	1.9M
Total Assets	38.3K	14.8M	42.5M	24.9M	14.5M	18.3M
Short Long Term Debt Total	373.8K	319.0K	248.9K	351.3K	622.0K	393.9K
Total Stockholder Equity	(4.5M)	9.8M	38.4M	21.0M	11.0M	13.7M
Net Debt	355.3K	(13.6M)	(40.5M)	(6.8M)	(8.5M)	(9.0M)
Cash	18.5K	14.0M	40.8M	7.2M	9.2M	13.1M
Cash And Short Term Investments	18.5K	14.0M	40.8M	23.1M	13.3M	16.8M
Common Stock Shares Outstanding	1.7M	1.7M	3.0M	4.2M	5.3M	3.2M
Liabilities And Stockholders Equity	38.3K	14.8M	42.5M	24.9M	14.5M	18.3M
Non Current Liabilities Total	275.4K	276.5K	2.7M	205.5K	90.1K	85.6K
Other Current Assets	16.9K	829.2K	1.6M	163.5K	959.0K	729.2K
Other Stockholder Equity	7.7M	24.8M	68.2M	68.8M	77.9M	46.4M
Total Liab	4.5M	5.0M	4.1M	3.9M	3.5M	3.3M
Net Invested Capital	(4.1M)	10.1M	38.7M	21.0M	11.0M	14.0M
Net Working Capital	(4.2M)	10.1M	38.4M	20.7M	10.8M	13.4M
Short Term Debt	98.4K	42.5K	248.9K	145.8K	531.9K	558.5K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC